15.69
Adma Biologics Inc stock is traded at $15.69, with a volume of 1.79M.
It is up +1.75% in the last 24 hours and up +9.26% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$15.42
Open:
$15.35
24h Volume:
1.79M
Relative Volume:
0.52
Market Cap:
$3.67B
Revenue:
$474.17M
Net Income/Loss:
$208.93M
P/E Ratio:
18.47
EPS:
0.8493
Net Cash Flow:
$65.61M
1W Performance:
-2.12%
1M Performance:
+9.26%
6M Performance:
-20.31%
1Y Performance:
-19.70%
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ADMA
Adma Biologics Inc
|
15.69 | 3.67B | 474.17M | 208.93M | 65.61M | 0.8493 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Why ADMA Biologics Inc. stock appeals to analystsWeekly Trend Recap & Daily Profit Maximizing Trade Tips - newser.com
Will ADMA Biologics Inc. stock continue dividend increases2025 Trading Volume Trends & Stock Timing and Entry Methods - newser.com
Can ADMA Biologics Inc. stock attract ESG capital inflows2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Applying Wyckoff theory to ADMA Biologics Inc. stock2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - sharewise.com
Risk adjusted return profile for ADMA Biologics Inc. analyzedJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors - sharewise.com
ADMA Biologics Inc Stock Analysis and ForecastVolatility Adjusted Trading & Actionable Entry & Exit Points Daily - earlytimes.in
Why ADMA Biologics' (NASDAQ:ADMA) Earnings Are Weaker Than They Seem - Yahoo Finance
Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade - sharewise.com
(ADMA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Adma Biologics Shares Maintain Upward Momentum on Strong Financial Performance - AD HOC NEWS
Is ADMA Biologics Inc a good long term investmentEmerging Market Stocks & Capital Planning and Optimization - earlytimes.in
ADMA Biologics (ADMA) Is Down 8.1% After Raising Revenue Guidance Through 2029 Has The Bull Case Changed? - Yahoo Finance
ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc earnings matched, revenue topped estimates By Investing.com - Investing.com Australia
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales - sharewise.com
ADMA Biologics Inc. Reports Strong Q3 Earnings Call - TipRanks
ADMA Biologics Ups Guidance After Outpacing Revenue Estimates - Finimize
ADMA Biologics (ADMA) Reports Record Revenue Growth in Q3 2025 - GuruFocus
ADMA Biologics Reports Strong Q3 2025 Financial Results - The Globe and Mail
ADMA Biologics Inc earnings matched, revenue topped estimates - Investing.com India
Adma Biologics: Q3 Earnings Snapshot - CT Insider
ADMA Biologics Inc (ADMA) Q3 2025 Earnings Call Highlights: Record Growth and Strategic Advancements - Investing.com Canada
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics Inc (ADMA) Q3 2025 Earnings Call Highlights: Reco - GuruFocus
ADMA Raises Financial Projections, Boosts FY26 EBITDA Forecast - GuruFocus
Adma Biologics (ADMA) Q3 Earnings Match Estimates - sharewise.com
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update - The Globe and Mail
Earnings call transcript: ADMA Biologics Q3 2025 sees steady revenue growth - Investing.com Nigeria
Biopharmaceutical firm ADMA's Q3 revenue beats estimates - MarketScreener
ADMA Outlines Strategic Vision for Earnings Growth and Value Cre - GuruFocus
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
ADMA Q3 Revenue Surpasses Expectations, Signals Strong Future Gr - GuruFocus
ADMA Biologics (ADMA) Q3 Revenue Surpasses Expectations - GuruFocus
ADMA Biologics Inc Surpasses Q3 2025 Expectations with EPS of $0 - GuruFocus
Earnings Flash (ADMA) ADMA Biologics, Inc. Reports Q3 Revenue $134.2M, vs. FactSet Est of $130.5M - MarketScreener
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):